Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations research uncovered that conolidine interacts While using the atypical chemokine receptor